Cobimetinib (formerly GDC-0973/XL518)

Cobimetinib, an inhibitor of the MEK pathway, is being developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement with Exelixis.

Partnered Compounds

We have established multiple partnerships and collaborations with other leading pharmaceutical and biopharmaceutical companies. These partnerships are designed to advance the development of a variety of promising therapies for cancer and other serious diseases.